Inhibitors of aldose reductase and advanced glycation end-products formation from the leaves of Stelechocarpus cauliflorus R.E. Fr.

Two dihydroflavonol glycosides, engeletin and astilbin, were isolated from an EtOAc extract of the leaves of Stelechocarpus cauliflorus R.E. Fr. (Annonaceae). The inhibitory activity of engeletin against a recombinant human aldose reductase (IC50 value=1.16 microM) was twice that of quercetin as a positive control (2.48 microM), and 23 times greater than that of astilbin (26.7 microM). Engeletin inhibited the enzyme uncompetitively. Astilbin was about as potent as the positive control, quercetin, in its inhibition of advanced glycation end-products formation. These flavonoids displayed therapeutic potential in the prevention and treatment of diabetic complications.

[1]  N. Sharpless,et al.  Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. , 1985, Journal of medicinal chemistry.

[2]  W. Chou,et al.  Protection against oxidative damage by dihydroflavonols in Engelhardtia chrysolepis. , 1996, Bioscience, biotechnology, and biochemistry.

[3]  W. Chou,et al.  Inhibition of aldose reductase by dihydroflavonols inEngelhardtia chrysolepis and effects on other enzymes , 1996, Experientia.

[4]  M. Cooper,et al.  The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. , 2005, Current drug targets.

[5]  A. Waiss,et al.  Structural relations and interconversions of isomeric astilbins , 1975 .

[6]  T Tanimoto,et al.  Purification and characterization of the recombinant human aldose reductase expressed in baculovirus system. , 1991, Biochimica et biophysica acta.

[7]  K. Inagaki,et al.  Inhibition of aldose reductases from rat and bovine lenses by flavonoids. , 1982, Biochemical pharmacology.

[8]  D. Kitts,et al.  Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative , 2003, Molecular and Cellular Biochemistry.

[9]  V. S. Manickam,et al.  Determination of Aglycone Chirality in Dihydroflavonol 3-O-α-L-Rhamnosides by ^1H-NMR Spectroscopy , 1995 .

[10]  K. Yoshida,et al.  Protein glycation inhibitors from thyme (Thymus vulgaris). , 1995, Bioscience, biotechnology, and biochemistry.

[11]  R. Wada,et al.  Role of Advanced Glycation End Products and Their Receptors in Development of Diabetic Neuropathy , 2005, Annals of the New York Academy of Sciences.

[12]  Sonia Manzanaro,et al.  Aldose reductase inhibitors from natural sources. , 2003, Natural product reports.

[13]  W. Chou,et al.  Inhibition of aldose reductase and sorbitol accumulation by astilbin and taxifolin dihydroflavonols in Engelhardtia chrysolepis. , 1997, Bioscience, biotechnology, and biochemistry.

[14]  J. Wautier,et al.  Advanced glycation end products, their receptors and diabetic angiopathy. , 2001, Diabetes & metabolism.

[15]  M. Ubukata,et al.  Screening System for the Maillard Reaction Inhibitor from Natural Product Extracts , 2002 .

[16]  D. Aronson.  Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes , 2003, Journal of hypertension.

[17]  J. Kinoshita,et al.  Inhibition of lens aldose reductase by flavonoids--their possible role in the prevention of diabetic cataracts. , 1976, Biochemical pharmacology.

[18]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[19]  Nessar Ahmed,et al.  Advanced glycation endproducts--role in pathology of diabetic complications. , 2005, Diabetes research and clinical practice.

[20]  D. H. Silva,et al.  Flavonoids from Iryanthera sagotiana , 1997 .